Analysts Have Turned On TG Therapeutics, Inc. (TGTX)

Taking everything into account, TG Therapeutics, Inc. (NASDAQ:TGTX) scores 80% Buy on the technical side. The stock is also flashing a Buy from the Barchart TrendSpotter trading system. Traders hoping to speculate on the TGTX’s short-term trajectory should know that short terms indicators for the stock averaged 80% Buy with an average daily trading volume over the past 20 days at 2991060 shares. TGTX stock has overall a 0.5% Buy signal considering medium term indicators and the 50-day average daily volume remained almost 2065010 shares. It’s also worth noting that the stock, whose average daily volume over the 100 days prior to this writing was shares, is 100% Buy on the basis of long term indicators.

The share price is currently staying around the first support level of $6.79. Below this, the next support is placed in the zone of $6.64. Till the time, the TGTX stock trades above this level, bulls have nothing to fear. On momentum oscillators front, ‘RSI’ has touched 69.64 on daily chart, which may remain a cause for concern. If the price breaks below $6.64 level on closing basis, then we may see more profit booking and the stock may show further weakness. On the flipside, hitting the $7.09 mark may result into a pull-back move towards $7.24 level.

TG Therapeutics, Inc. (TGTX) is projected to climb by 123.02 percent over the next 12 months, according to price target estimates compiled by finviz. Meanwhile, they have set a $27-month high price target. This represents a whopping 288.49 percent increase from where shares are trading today. The 12-month median price target assigned by the analysts stands at $13.5, which represents a return potential of 94.24 percent when compared to the closing price of the stock of $6.95 on Thursday, March 14. The lowest price target for the stock is $9 — slightly more than 29.5 percent from TGTX’s current share price.

Here’s a rundown of insider trading activity for sense of TG Therapeutics, Inc. (NASDAQ:TGTX).

TGTX shares accumulated 0.15 points or 2.21 percent on Thursday to $6.95 with a heavy trade volume of 2.393 million shares. After opening the session at $6.81, the shares went as high as $7.0799 and as low as $6.78, the range within which the stock’s price traded throughout the day. The firm is left with a market cap of $583 million and now has 83.84 million shares outstanding. TG Therapeutics, Inc. (TGTX) stock has gained 53.42 percent of market value in 21 trading days.

Analysts at Jefferies, assumed coverage of TG Therapeutics, Inc. (NASDAQ:TGTX) with Buy recommendation, according to their opinion released on February 06. Raymond James analysts have downgraded their rating of TGTX stock from Strong Buy to Outperform in a separate flash note to investors on September 25. Analysts at B. Riley FBR, Inc. are sticking to their Buy recommendation. However, on March 09, they lifted target price for these shares to $27 from $21.50. Analysts at B. Riley FBR, Inc., made their first call for the stock with a Buy rating, according to a research note that dated back to March 09.

TGTX stock has a trailing 3-year beta of 2.3, offering the possibility of a higher rate of return, but also posing more risk. The portion of a company’s profit allocated to each outstanding share of common stock was -$2.3 a share in the trailing twelve months. The stock’s value has surged 69.51 percent year to date (YTD) against a decline of -58.63 percent in 12 month’s time. The company’s shares still trade -58.88 percent away from its 1-year high of $16.90 and 109.34 percent up from 52-week low of $3.32. The average consensus rating on the company is 1.6, on a scale where 5 equates to a unanimous sell rating. In short, the mean analyst recommendations are calling this stock a buy.

Shares of TG Therapeutics, Inc. (TGTX) are trading at a P/E ratio of 0 times earnings reported for the past 12 months. The industry TGTX operates in has an average P/E of 86.9. Its P/E ratio went as low as 0X and as high as 0 over the 5-year span. Further, it is sporting a 2913.44 on the Price-to-Sales ratio. Compare this with the industry average P/S of 47.58. 0 percent is the gross profit margin for TG Therapeutics, Inc. and operating margin sits at 0 percent. Along with this, the net profit margin is 0 percent.

TGTX will be declaring its Q4 financial results on March 07. Analysts are forecasting revenue to climb 5.3 percent to $40M in the next fiscal quarter, while earnings are seen soaring by nearly -28.81 percent to -$0.42 per share. History has shown that shares in TG Therapeutics, Inc. have gone down on 13 different earnings reaction days and are predicted to add 0.05 percent when the company reports upcoming earnings. In last reported earnings results, it earned -$0.69 per share, worse than the -$0.44, adjusted, expected by Thomson Reuters consensus estimate. Revenue was $40000, better than the $30000 analysts expected. Earnings are estimated to increase by -20.4 percent this year, 3.3 percent next year and continue to increase by 0 percent annually for the next 5 years.